Lung cancer

Lung Cancer

Lung cancer remains the leading cause of cancer deaths in the United States. However, clinical advances in screening and treatment paradigms for lung cancer are improving outcomes for these patients. Lung cancer CME and CE is essential for clinicians to stay current with these evolving treatment options.

Important recent shifts in the treatment paradigm include the expanding role of immune checkpoint inhibitors for lung cancer as well as targeted therapies for an increasing list of therapeutically actionable driver mutations. In every case, continuing education regarding the optimal use of each of the available treatment options is critical, including patient selection, dosing and administration, and best practices for monitoring for adverse events.

Lung cancer CME is vital to developing and increasing the clinical skills, knowledge, and professional performance needed to effectively provide good care for patients with this disease.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?